Jazz Pharmaceuticals Sees FY23 Adj. EPS $18.15-$19 Vs $18.66 Est.; Revenue $3.750B-$3.875B Vs $3.83B Est.
Portfolio Pulse from Benzinga Newsdesk
Jazz Pharmaceuticals has projected its FY23 adjusted EPS to be between $18.15 and $19, compared to the estimated $18.66. The company also expects its revenue to be between $3.750B and $3.875B, against the estimated $3.83B.
November 08, 2023 | 10:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Jazz Pharmaceuticals' FY23 adjusted EPS and revenue forecasts are slightly higher than estimates. This could potentially lead to a positive market reaction.
Jazz Pharmaceuticals' projected FY23 adjusted EPS and revenue are both higher than the estimates. This indicates that the company is confident about its future performance, which could potentially lead to a positive market reaction. However, the actual impact will depend on various factors, including the overall market conditions and investor sentiment towards the company.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100